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Pyrazinamide (PZA) is active against major Mycobacterium tuberculosis species (M. tuberculosis, M. africanum, and M. microti)
but not againstM. bovis andM. avium. The latter two are mycobacterial species involved in human and cattle tuberculosis and
in HIV coinfections, respectively. PZA is a first-line agent for the treatment of human tuberculosis and requires activation by a
mycobacterial pyrazinamidase to form the active metabolite pyrazinoic acid (POA). As a result of this mechanism, resistance to
PZA, as is often found in tuberculosis patients, is caused by point mutations in pyrazinamidase. In previous work, we have
shown that POA esters and amides synthesized in our laboratory were stable in plasma (M. F. Simões, E. Valente, M. J. Gómez, E.
Anes, and L. Constantino, Eur J Pharm Sci 37:257–263, 2009, http://dx.doi.org/10.1016/j.ejps.2009.02.012). Although the amides
did not present significant activity, the esters were active against sensitive mycobacteria at concentrations 5- to 10-fold lower
than those of PZA. Here, we report that these POA derivatives possess antibacterial efficacy in vitro and ex vivo against several
species and strains ofMycobacterium with natural or acquired resistance to PZA, includingM. bovis andM. avium. Our results
indicate that the resistance probably was overcome by cleavage of the prodrugs into POA and a long-chain alcohol. Although it is
not possible to rule out that the esters have intrinsic activity per se, we bring evidence here that long-chain fatty alcohols possess
a significant antimycobacterial effect against PZA-resistant species and strains and are not mere inactive promoieties. These
findings may lead to candidate dual drugs having enhanced activity against both PZA-susceptible and PZA-resistant isolates and
being suitable for clinical development.
Mycobacterium tuberculosis is a particularly successful patho-gen which latently infects about 2 billion people, almost one-
third of the world’s population (1). Each year, there are about 8
million new cases of tuberculosis (TB) and 1.3 million deaths
worldwide. Fifty million people have already been infected with
drug-resistant TB (1). This situation arose from (i) the spread of
HIV worldwide, a virus that weakens the immune system, allow-
ing the reactivation of latent drug-susceptible or drug-resistantM.
tuberculosis strains, and (ii) noncompliance, often due to toxic
side effects during the long-lasting treatment.
Pyrazinamide (PZA) is an important frontline anti-TB drug
that plays a key role in shortening TB therapy from 9 to 12 months
to the current 6 months (2). The ability of PZA to shorten TB
therapy is due to its activity against a population of nongrowing,
persistent tubercle bacilli residing in an acidic pH phagosomal
environment that is not killed by other anti-TB drugs (3–5). Fur-
thermore, studies have shown that a regimen of PZA combined
with rifampin for 2 months is as effective at preventing TB in HIV
carriers as a 6-month isoniazid treatment (6).
The Cynamon group postulated in 1992 that pyrazinamide was
converted to pyrazinoic acid (POA) within the bacterial lumen
and that POA was the active antimycobacterial agent (7). Indeed,
PZA is a prodrug whose activation requires hydrolysis by the pyr-
azinamidase enzyme encoded by the pncA gene of M. tuberculosis
(2, 3). The unique susceptibility ofM. tuberculosis to PZA is at least
partly due to an inefficient efflux mechanism that allows POA to
be increasingly accumulated in the acidic interior of M. tubercu-
losis (2).
While acquired resistance to PZA in M. tuberculosis occurs
mainly by mutations in the pncA gene (8), the mechanism of nat-
ural PZA resistance in other mycobacteria is more complex. Like
M. tuberculosis, M. bovis strains, including BCG, are naturally re-
sistant to PZA due to a single point mutation (C¡G) at nucleotide
position 169 in pncA (9). In contrast, naturally PZA-resistant M.
smegmatis and other bacteria, such as Escherichia coli, have a
highly active POA efflux mechanism that prevents the accumula-
tion of POA even at acidic pH (10). M. avium has high pyrazi-
namidase activity, and its natural resistance to PZA probably is
due to the POA efflux mechanism (11).
If PZA is a prodrug, then it would be possible to develop alter-
native prodrugs that deliver POA intracellularly. This hypothesis
was successfully developed by the work of Cynamon et al. in a
series of papers dedicated to exploring the potential of such esters
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as antituberculosis agents (7, 12, 13). The advantage of these com-
pounds seems evident; because esterases are abundant in myco-
bacteria, prodrugs can be easily activated in situ. Moreover, resis-
tant strains will hardly be selected, as the mechanism would no
longer depend on a single gene point mutation. Esterases also exist
in human plasma; therefore, these esters may be hydrolyzed be-
fore reaching their bacterial target, their active moiety (POA) be-
ing too polar for effective permeation into mycobacteria (12–14).
In order to improve the stability of the POA esters, we designed
and synthesized several long-chain esters, showing that esters with
long alkoxy chains are particularly resistant to hydrolysis in the
plasma (14). This fact suggested that it is possible to identify some
POA ester prodrugs with increased resistance toward plasmatic
hydrolysis. Here, we demonstrate that such POA ester prodrugs
are active against PZA-resistant M. tuberculosis isolates as well as
against naturally PZA-resistant species of mycobacteria, such as
M. bovis and M. avium. Our results indicate that their resistance
was overcome by two factors, the release of POA by enzymes other
than pyrazinamidase and the intrinsic antimycobacterial effect of
long-chain alkanols.
The new compounds were shown to possess in vitro and ex vivo
activities within macrophages infected with sensitive strains of M.
tuberculosis or M. avium even at concentrations 10- to 100-fold
lower than those of PZA.
MATERIALS AND METHODS
Materials. Balanced salt solution, phosphate-buffered saline (PBS), Dul-
becco’s modified Eagle’s medium (DMEM), and L-glutamine were pur-
chased from Invitrogen. Sodium dodecyl sulfate (SDS), Triton X-100,
pyrazinamide (PZA), pyrazinoic acid (POA), n-dodecanol (12-ol), n-tet-
radecanol (14-ol), n-hexadecanol (16-ol), n-butanol (4-ol), and trypan
blue were purchased from Sigma-Aldrich Quimica SA. Middlebrook
7H10 agar was purchased from Difco. The materials and equipment used
for antibiotic susceptibility tests of M. tuberculosis with the Bactec MGIT
960 PZA kit system were purchased from Becton Dickinson and prepared
according to the recommendations of the manufacturer. Microwell tissue
culture plates were purchased from Nunc. Pyrazinamide and the esters of
POA, namely, E-12 (n-dodecyl pyrazinoate), E-14 (n-tetradecyl pyrazino-
ate), and E-16 (n-hexadecyl pyrazinoate), were synthesized as described
previously (14). They then were prepared in stock solutions of 8 mg/ml in
dimethyl sulfoxide (DMSO), diluted in Middlebrook 7H9 medium con-
taining ADC (albumin, dextrose, and catalase; oleic acid was not included,
as it is toxic for mycobacteria at acidic pH [15]; Difco), and acidified to pH
5.9 (14).
Bacterial strains. M. tuberculosis H37Rv (ATCC 27294), a PZA-sus-
ceptible strain, served as the positive control; five clinical strains with
acquired resistance to PZA (multidrug-resistant [MDR]-TB) and main-
tained in the Unit of Bacteriology, Health Institute of Lisbon, Lisbon,
Portugal, were used as M. tuberculosis PZA-resistant strains (16). Two out
of the five clinical strains were selected for their susceptibility to POA. M.
bovis isolated from infected cattle was provided by the National Labora-
tory for Veterinary Research, Lisbon, Portugal. M. bovis BCG (CIP
105050) was purchased from the Pasteur Institute, Pasteur Collection,
Paris, France, and the two M. avium strains, DZMC 44156 and DZMC
44157, were from the German Collection (17). M. smegmatis ATCC 607
variant mc2155 was used for the production of the homogenate.
Activation of the prodrugs inM. avium and BCG homogenates.M.
avium homogenate and BCG homogenate were prepared using the tech-
nique described for M. smegmatis (14, 18). The incubation of the homog-
enate with prodrug was performed at 37°C in a total volume of 1,500 l.
The concentration of substrate in incubation media was 1.2  104 M,
and the protein concentration was 0.12 mg/ml. Dilutions were performed
using PBS. At predetermined time points, aliquots of 150 l were taken
into vials containing 300 l of acetonitrile and 300 l of a 1% ZnCl2
aqueous solution. The suspension then was agitated in a vortex and cen-
trifuged for 5 min. The supernatant was injected into a high-performance
liquid chromatographer (HPLC), as described previously (14), for quan-
tification of the prodrug and POA.
Determination of the MICs. The MICs of PZA, POA, the long-chain
ester prodrugs of POA (E-12, E-14, and E-16), and the corresponding
long-chain fatty alcohols used as promoieties (12-ol, 14-ol, and 16-ol)
were determined individually by two methods, the broth dilution
method, available in our laboratory (19), and the Bactec MGIT 960 PZA
kit provided by the National Health Institute, as described previously
(16). Briefly, five MDR-TB isolates and the susceptible M. tuberculosis,
used as a reference, were tested for susceptibility to PZA by the Bactec
MGIT 960 PZA kit at a reduced pH of 5.9 and a 100 g/ml concentration
of PZA (Becton Dickinson) according to the manufacturer’s manual. We
retested these five MDR-TB strains for PZA susceptibility by using the
Bactec MGIT 960 PZA with 100, 300, and 900 g/ml concentrations of
PZA. In parallel, we used the dilution method, screening drug concentra-
tions ranging from 5 to 1,000 g/ml for the same M. tuberculosis strains
tested by the Bactec system for M. bovis, M. bovis BCG, and M. avium. The
acidified Middlebrook 7H9 medium (pH 5.9) was supplemented with
ADC (Difco) (14) and an adjusted concentration of mycobacteria (ap-
proximately 105 CFU). Each agent or prodrug screened in serial dilutions
was incubated for 10 days at 37°C. For the long-chain alkanols, the pH was
adjusted to 7 as usual for compounds other than POA prodrugs. The MIC
was the minimum drug concentration where no visible turbidity was ob-
served. The assay was extended until day 30. A test tube without drug was
used as the control. The MIC values obtained were similar in the two
methods.
Macrophage cell line J774A.1. The J774 macrophage cell line was
kindly provided by Gareth Griffiths, EMBL, Heidelberg, Germany, and
was maintained as described previously (17).
Macrophage infection and ex vivo intracellular killing activity. Bac-
terial cultures in the exponential growth phase were pelleted, washed
twice in PBS (pH 7.4), and resuspended in DMEM to a final optical den-
sity at 600 nm (OD600) of 0.1, corresponding to 10
7 colony-forming mi-
croorganisms per ml. Clumps of bacteria were removed by ultrasonic
treatment of bacterial suspensions in an ultrasonic water bath for 15 min,
followed by low-speed centrifugation at 120  g for 2 min. Single-cell
suspension was verified by light microscopy. J774 cells were seeded onto
24-well tissue culture plates at a density of 0.5 105 cells per well and were
incubated for 2 days until 80% confluence and infected with bacteria at a
multiplicity of infection of 10:1. After 3 h of bacterial internalization by
macrophages at 37°C and 5% CO2, remaining extracellular bacteria were
removed by intensive washing with PBS. The prodrugs then were added to
the medium and incubated for 7 days. Every second day, the medium was
replaced with fresh medium containing the test compound.
At the end of the bacterial internalization by macrophages (3 h) and
after 1, 3, 5, and 7 days postinfection, macrophages were washed with PBS
and disrupted with 1% IGEPAL CA-630 (Sigma-Aldrich) solution in wa-
ter, a nonionic, nondenaturing detergent that disrupts eukaryotic cells but
does not affect mycobacterial viability, with the goal being to assess the
colony-forming microorganisms of viable intracellular bacteria.
Serial dilutions of the macrophage culture lysate were prepared in
water and plated in Middlebrook 7H10 agar medium supplemented with
oleic acid-albumin-dextrose-catalase (OADC; Difco). After about 3 weeks
of incubation at 37°C, colonies were counted. The proportion of surviving
mycobacteria in samples treated with the compounds was compared to
controls of infected cells at the same time point treated with the same
dilution of the dilution solvent (mock control) and was taken as a measure
of the in vivo activity of the screened compounds. The assays were done in
triplicate and from independent experiments.
Cytotoxicity assay. J774A.1 cells were incubated with the compounds
at concentrations of 20g/ml for esters E-12, E-14, and E-16 and at 5 and
10 g/ml for the n-alkanols 12-ol, 14-ol, and 16-ol for 5 days. Culture
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media with the compounds was replenished every second day during the
course of the experiment. DMSO, at the same proportions as those in the
tested compounds, was used as a control. The highest concentration of
DMSO used was 1%. Puromycin (Sigma-Aldrich) was used as a positive
control for cell death. Cell viability was determined after 5 days of treat-
ment using alamarBlue (Molecular Probes) by following the manufactur-
er’s indications. Briefly, 10% (vol/vol) alamarBlue reagent was added to
each well and incubated for 4 h at 37°C and 5% CO2. Fluorescence was
measured at an excitation of 570 nm and emission of 595 nm in a
TecanM200 plate spectrophotometer. Viability was calculated as percent
fluorescence intensity relative to that of the untreated controls. Test re-
sults were obtained from at least four independent experiments, each
performed in triplicate.
Statistical analysis. All values are reported as means  standard de-
viations (SD) from 3 independent experiments. The statistical signifi-
cance of the differences observed in bacterial loads was analyzed by the
Student t test. Differences were considered significant at P  0.05 (*) or
P 0.01(**).
RESULTS
Hydrolysis of the esters. Figure 1 shows the structures of the es-
ters and alcohols used in this study and also the hydrolysis reaction
to POA and the corresponding alcohol. The incubation of the
esters with mycobacterial homogenate (BCG or M. avium) gives
rise to POA and the corresponding alcohol. As can be seen from
Fig. 1, the disappearance of the ester corresponds quantitatively to
the formation of POA.
Effect of PZA, POA, and POA esters on PZA-susceptible and
-resistant mycobacteria in vitro. The calculated MICs of PZA,
POA, and POA esters (PAEs) are summarized in Table 1 for a pH
of the medium adjusted to 5.9. As expected, the results for PZA are
in agreement with the literature, with a MIC of 10 to 20 g/ml at
pH 5.5 (20) and 100g/ml at pH 5.9 (16, 21). By using exactly the
same conditions, all three POA esters displayed a 5-fold lower
MIC than PZA or POA in vitro against the M. tuberculosis-suscep-
tible strain.
When PZA-resistant strains of M. tuberculosis or naturally re-
sistant species, such as M. avium and M. bovis, including BCG,
were used to screen the new agents, the results were as depicted in
Table 1. While PZA has a MIC higher than 1,000 g/ml for all
strains and species tested, confirming their resistance, the esters
E-12 and E-14 (obtained from 12-ol and 14-ol, respectively)
showed MICs of 10 to 40 g/ml, indicating their efficacy against
PZA-resistant mycobacteria. For E-16 (n-hexadecyl pyrazinoate),
the MIC was slightly higher than those for E-12 and E-14 but still
two orders of magnitude lower than those of PZA against resistant
mycobacteria.
The results also indicate that POA, with a MIC similar to that of
Ester POA Alcohol
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FIG1 Hydrolysis reaction of pyrazinoate esters to POA and the corresponding alcohol and structure of the compounds studied. The concentrations of ester E-12
and POA during the hydrolysis of E-12 in M. bovis BCG or M. avium homogenates are shown.
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PZA in sensitive strains, is active against PZA-resistant mycobac-
teria except M. avium. Indeed, the differences observed between
M. tuberculosisH37Rv and theM. tuberculosisPZA-resistant strain
with sensitivity to POA indicates that the resistance on these M.
tuberculosis clinical strains is due to a mutation in pyrazinamidase,
as confirmed by DNA sequencing of the pncA gene (16). For all M.
avium strains tested, resistance against PZA and, indeed, POA was
detected with MICs higher than 1,000 g/ml. However, all POA
esters (E-12 to E-16) were shown to possess antimycobacterial
activity againstM. avium, with MICs ranging from 10 to 40g/ml.
Antibacterial effects of the pyrazinoate esters on susceptible
and resistant mycobacteria in infected macrophages. We first
determined the MIC of each PAE against an intracellular M. tu-
berculosis susceptible strain. For each compound we selected a
range of concentrations above and below the in vitroMIC, ranging
from 10 to 200 g/ml. Figure 2A shows the antimycobacterial
effects on the susceptible strain within J774 macrophages. The
percentage of intracellular survival is represented at days 0, 1, 3, 5,
and 7. The culture medium with the drug was added 3 h postbac-
terial internalization by macrophages and was replaced every sec-
ond day. For PZA and POA, the ex vivo active concentration was
100 g/ml, while for the PAEs E-12, E-14, and E-16 it was 20
g/ml, confirming an ex vivoMIC similar to that obtained in vitro.
Lower concentrations of these compounds were ineffective in in-
fected macrophages. On day one postinfection, all of the com-
pounds were effective against M. tuberculosis. E-12 and E-14, at a
concentration 5-fold lower than that of PZA or POA, presented an
approximately 50% higher antimycobacterial activity than that of
PZA and POA (Fig. 2A). This activity was maintained throughout
the experiment. At day seven postinfection, the activity of the
esters was significantly more effective against intracellular myco-
bacteria than PZA or POA (Fig. 2A).
Since ester E-12 had higher activity against intracellular sus-
ceptible M. tuberculosis and a MIC of 10 to 20 g/ml against two
strains of M. avium, we selected this compound to determine its
activity against intracellular M. avium. Figure 2B shows how its
activity evolved during the days following infection, emphasizing
its effects on intracellular survival rate compared to those of PZA
and POA. As the MIC determined in vitro for M. avium DZMC
44156 was 20 g/ml at pH 5.9, we chose to test three concentra-
tions below the MIC in infected macrophages. The concentration
found to be effective was 10 g/ml with a 50% decrease of intra-
cellular M. avium from day 3 postinfection relative to those of
PZA- or POA-treated cells (Fig. 2B).
Mycobacterium avium is naturally resistant to most antibiotics,
including PZA. Unlike M. tuberculosis, whose PZA resistance is
due to mutations in the pncA gene, M. avium has high PZase
activity. M. avium natural resistance to PZA most likely is due to a
POA efflux mechanism, but this mechanism has not been fully
proven so far (11). The MICs shown in Table 1 clearly suggest that
M. avium is resistant to POA, in contrast to the other tested my-
cobacteria. This led us to investigate the effect of these POA esters
against the two M. avium reference strains. Incubation of esters
with anM. avium homogenate gives rise to quantitative hydrolysis
of the POA esters to POA (Fig. 1). Because POA did not present
activity when tested against M. avium (Table 1), we decided to test
TABLE 1 MICs of POA esters POA and PZA in vitro
Compounda
MICb (g/ml)
M. bovis
BCG M. bovis
M. avium
44156
M. avium
44157
M. tuberculosis
H37Rv
M. tuberculosis
PZAR1
M. tuberculosis
PZAR2
E-12 20 40 20 10 20 40 20
E-14 20 40 20 10 20 40 20
E-16 40 40 40 40 20 40 40
PZA 1,000 1,000 1,000 1,000 100 1,000 1,000
POA 100 100 1,000 1,000 100 100 100
a E-12, n-dodecyl pyrazinoate; E-14, n-tetradecyl pyrazinoate; E-16, n-hexadecyl pyrazinoate; PZA, pyrazinamide; POA, pyrazinoic acid.
b rM. tuberculosis H37Rv is the reference sensitive strain. All other species and strains are resistant to PZA.
%
 o
f 
su
rv
iv
a
l
0
30
60
90
120
Time (days)
0 1 3 5 7
Control
PZA
POA
20 µg/ml E-12
20 µg/ml E-14
20 µg/ml E-16
%
 o
f 
su
rv
iv
a
l
0
30
60
90
120
Time (days)
0 1 3 5 7
Control
PZA
POA
  2.5 µg/ml E-12
  5 µg/ml E-12
10 µg/ml E-12
B.
A.
*
****
**
*
*
**
**
**
**
*
Mycobacterium tuberculosis H37rv
Mycobacterium avium DSMZ44156
FIG 2 Ex vivo antibacterial effects of POA esters on mycobacteria. The ordi-
nate represents the percentage of remaining intracellular survival measured by
CFU/ml along 7 days postinfection. (A) Effects of E-12, E-14, and E-16 on
intracellular M. tuberculosis compared to those of PZA and POA. (B) Effect of
E-12 on M. avium within J774 macrophages. PZA and POA were used to
confirm the natural resistance of M. avium to these compounds. The statistical
significance of the differences observed in bacterial loads was analyzed by the
Student t test. Differences were considered significant at P  0.05 (*) or P 
0.01 (**).
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the liberated long-chain alcohols, as these are likely candidates to
account for antimycobacterial activity. Therefore, we examined
alcohols with alkyl chain lengths from C4 to C16 and determined
their MICs against different mycobacteria strains, including M.
avium, as depicted in Table 2.
As expected, all long-chain alcohols displayed an antimycobac-
terial activity slightly higher than that of POA esters, with MICs
ranging from 5 to 40 g/ml and efficacy increasing with chain
length.
Interestingly, Kushner et al. (22) obtained relevant antimyco-
bacterial activity with ethyl thiopyrazinoate and also found that
ethanethiol, the potential liberated thiol, presented very good ac-
tivity (even higher than that of the ester) when tested alone, shift-
ing the focus of their research from the pyrazine nucleus to thiol
moieties.
Antibacterial effect of the long-chain alcohols against intra-
cellular mycobacteria. We next tested the effect of long-chain
alkanols on the intracellular survival of PZA-resistant mycobacte-
ria. Effects of the long-chain alcohols on the intracellular survival
of M. tuberculosis in macrophages were determined first. The
greatest effects on bacterial killing were observed after 5 or more
days of incubation. The results shown in Fig. 3 show that the
12-carbon alcohol was most effective at killing the bacteria at 5
days postinfection. Although the 12-carbon alcohol usually was
less effective on most strains in broth culture than its homologs,
inside macrophages the 12-ol was very effective. The PZA-resis-
tant strain of M. tuberculosis demonstrated comparable sensitivi-
ties to 100 g/ml POA and to 12-ol at 10 g/ml. No differences
were observed between the M. tuberculosis reference strain H37Rv
relative to the PZA-resistant strain for all compounds with the
exception of PZA (compare Fig. 2A, day seven postinfection, to
Fig. 3B, left).
In this context, n-dodecanol again proved to be the most
active n-alkanol screened. We then compared the effect of
12-ol to that of the corresponding POA ester E-12 on the in-
tracellular killing of the M. tuberculosis PZA-resistant strain
and/or M. avium DZMC44156 7 days postinfection. The results
(Fig. 3B, right) show that comparable effects were caused by 10
TABLE 2 MICs of the n-alkanols in vitro
Compound
MIC (g/ml)
M. bovis
BCG
M. avium
44156
M. avium
44157
M. tuberculosis
H37Rv
4-ola 80 80 80 10
12-ol 10 40 40 5
14-ol 5 20 20 5
16-ol 5 20 20 5
Kanamycin 0.5 10 10 1
a 4-ol (butanol) was used to estimate the effect of a short-chain alcohol.
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FIG 3 Ex vivo antibacterial effects of long-chain alkanols and corresponding E-12 ester on PZA-resistant mycobacteria. (A) Effects on intracellular M.
tuberculosis of long-chain alkanols. (B) Effects on M. tuberculosis and on M. avium of 12-ol compared with those of PZA and POA (100 g/ml) and the
corresponding PZA ester E-12. The statistical significance of the differences observed in bacterial loads was analyzed by the Student t test. Differences were
considered significant at P 0.05 (*) or P 0.01 (**).
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g/ml E-12 and 5g/ml 12-ol, namely, 50% difference in survival
between PZA- and POA-treated infected cells in M. avium infec-
tion. As a reminder, one molecule of E-12 liberates one molecule
of dodecanol and one of POA; thus, 10 g of E-12 contains ap-
proximately 5 g of the corresponding alcohol. However, for M.
tuberculosis the results depicted in Fig. 3B (left) show a slightly
higher activity of the ester relative to that of 12-ol or POA alone.
Cytotoxicity evaluation of the new prodrugs and alkanols to
J774 cells. To confirm that the decrease in CFU after treatment
with the esters and long-chain alkanols were not due to potential
cytotoxicity against J774 cells, causing the loss of infected macro-
phages in the culture, the alamarBlue test was used as described in
Materials and Methods. The alamarBlue reagent allows the quan-
tification of cell viability by measuring their metabolic functions.
We verified that after 5 days of exposure, concentrations of prod-
rugs or n-alkanols equal to or below their MICs resulted in no
reduction of macrophage viability in noninfected control host
cells (Fig. 4). Cytotoxicity was tested in parallel for infected J774
cells for 7 days, but no effects were detected even at concentrations
10-fold higher than the MIC (not shown).
DISCUSSION
The present study has shown that POA esters are more effective in
clearing intracellular mycobacteria within J774 macrophages than
PZA or POA (Fig. 2A and B). It was found that 100 g/ml was an
appropriate concentration to distinguish between susceptible
strains (used as controls) and PZA-resistant M. tuberculosis.
Moreover, MICs higher than 1,000 g/ml were found for all my-
cobacteria that had natural or acquired resistance to PZA.
The POA esters, when tested against mycobacteria with natural
or acquired resistance, were shown to be active, with MICs rang-
ing from 5 to 80 g/ml. This was true for five drug-resistant M.
tuberculosis isolates and for M. bovis, including BCG. These are all
mycobacteria whose PZA resistance mechanism is related to mu-
tations in the pncA gene together with poor efflux pump mecha-
nisms characteristic of this group of microorganisms.
It is intriguing that with M. avium, a naturally PZA-resistant
species, both strains tested were highly susceptible to all esters but
resistant to POA. Cynamon et al. also reported that POA esters,
when obtained with similar alkanols (10-ol and 15-ol), presented
activity against M. avium (12).
Since tested POA did not show activity againstM.avium (Table
1), the activity presented by pyrazinoate esters could be due to
increased accumulation of POA inside the cells, intrinsic activity
of the ester molecules, or intrinsic activity of the alcohol moiety.
Regarding the first hypothesis, it is possible that POA is not
active against M. avium because it cannot penetrate inside the
bacteria; thus, the ester furnishes a way of delivering POA inside
the cell; however, it is likely that M. avium possesses an effective
POA efflux mechanism (11). If so, POA also should be expelled
from the mycobacteria after being formed by hydrolysis, making
the accumulation hypothesis less likely (unless the rate of entrance
supplants the rate of efflux).
Two possibilities remain: either the esters present antimyco-
bacterial activity per se or the alkanols have activity against M.
avium. Since pyrazinoic acid esters are easily hydrolyzed to the
corresponding alcohols in M. avium homogenate (Fig. 1), we fa-
vor the long-chain alcohols as the most likely agents accounting
for the observed antimycobacterial activity. Indeed, it can be seen
from Fig. 3B that the activity of the alkanol is comparable to the
activity of the ester. This is not surprising, as the activity of the
other moiety (POA) against M. avium is very low. It is known that
Tween 80, a detergent used to disperse clumps of mycobacteria in
liquid media cultures, can kill mycobacteria at acidic pH. Tween
80 releases oleic acid (23), and its structure has some similarities to
long-chain alkanols. Both have a long hydrocarbon chain with a
polar group capable of hydrogen bonding. Moreover, it is well
known that alcohols can easily be oxidized in vivo to carboxylic
acids (24, 25). Indeed, lethal effects of oleic acid and other fatty
acids against mycobacteria were reported (26, 27). Other reports
point to the lethal effect on M. tuberculosis of extracts of some
South African plants enriched with palmitic, oleic, and linoleic
acid and used to treat tuberculosis (28). More recently, the anti-
mycobacterial activities of C6 to C13 n-alkanols were examined
against M. smegmatis and M. tuberculosis H37Rv, with the best
antimycobacterial activity being found with 10-ol (29), very sim-
ilar to our 12-ol, for which we obtained the highest activity. The
alcohols 12-ol, 14-ol, and 16-ol have logP values of 4.2, 5.2, and
7.2, respectively (as calculated by ALOGPS) (30). It seems possible
that 14-ol and 16-ol, which are poorly soluble in water, do not
dissolve satisfactorily in the test medium, explaining why better
results are observed with alkanols of lower logP (4.2).
For M. tuberculosis, our results indicate that resistance was
overcome by the release of POA and by the antimycobacterial
effect of the long-chain alcohol released following POA ester hy-
drolysis (Fig. 3B, left), while forM. avium it is more likely that only
the 12-ol contributed to the antimycobacterial effect (Fig. 3B,
right). In a context of emergency with levels of MDR-TB increas-
ing the world over, these preliminary results should provide a
potential therapeutic alternative when other treatments have
failed. This approach, applied to other active moieties, may lead to
candidate dual drugs with enhanced activity against both PZA-
susceptible and PZA-resistant isolates suitable for clinical devel-
opment.
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